Lupin receives tentative approval from USFDA for Dapagliflozin and Saxagliptin tablets
Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US
Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
The National Sickle Cell Anaemia Elimination Mission was launched on 1st July 2023 at Shahdol, Madhya Pradesh
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
Marks remarkable acceleration in innovation using AI technology
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
Subscribe To Our Newsletter & Stay Updated